Incyte upgraded by Mizuho with a new price target
$INCY
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Mizuho upgraded Incyte from Neutral to Outperform and set a new price target of $121.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2026 | $107.00 | Overweight → Equal Weight | Wells Fargo |
| 12/8/2025 | $121.00 | Neutral → Outperform | Mizuho |
| 11/3/2025 | $125.00 | Neutral → Buy | Guggenheim |
| 10/8/2025 | Outperform → Perform | Oppenheimer | |
| 8/6/2025 | $89.00 | Equal Weight → Overweight | Wells Fargo |
| 8/1/2025 | $90.00 | Overweight | Barclays |
| 6/16/2025 | $107.00 | Hold → Buy | Stifel |
| 3/18/2025 | Buy → Neutral | Guggenheim |
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in Europe Globally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3 The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplati
Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET Q4 & YE 2025 Conference Call: February 10, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13758313 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in n
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (NASDAQ:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addi
144 - INCYTE CORP (0000879169) (Subject)
8-K - INCYTE CORP (0000879169) (Filer)
144 - INCYTE CORP (0000879169) (Subject)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
Wells Fargo downgraded Incyte from Overweight to Equal Weight and set a new price target of $107.00
Mizuho upgraded Incyte from Neutral to Outperform and set a new price target of $121.00
Guggenheim upgraded Incyte from Neutral to Buy and set a new price target of $125.00
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy
Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Incyte (NASDAQ:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company's legal and compliance teams. "Richard joins us with a distinguished background, including many years of experience as a partner at a premier law firm, and a proven track record advising biopharma companies on corporate governance, strategic transactions, intellectual property and litigation," said Bill Meury, President and Chief Executive Officer, Incyte. "He possesses exceptional legal acumen and sound judgment to help
Incyte (NASDAQ:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company's strategy and business development. "Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development," said Bill Meury, President and Chief Executive Officer, Incyte. "Dave will play a pivotal role in developing a coherent and e
Incyte (NASDAQ:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company's global human resources strategy including talent acquisition, organizational design and professional development. "Soni has extensive knowledge and experience in all aspects of human resources," said Bill Meury, President and Chief Executive Officer, Incyte. "She is a skilled professional and collaborative leader who will bring a strategic mindset and operational focus to the company. Soni will pla
Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET Q4 & YE 2025 Conference Call: February 10, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13758313 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in n
Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte's MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on
SC 13G - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)